Clinical data-IgA Nephropathy

Currently, the optimized immunosuppressive regimens for patients at moderate to high risk still need to be explored. Telitacicept is a recombinant TACI-Fc fusion protein that can simultaneously neutralize BLyS/BAFF and APRIL, inhibiting B cell differentiation into plasma cells that produce pathogenic Gd-IgA1.

This study aims to compare the short-term efficacy of the Telitacicept combined with glucocorticoid/immunosuppressant regimen versus the traditional immunosuppressant regimen (using glucocorticoid/immunosuppressant alone) in the treatment of IgAN in the real world.